As Director, Nonclinical Development, Andrew Emanuel has overall responsibility for programs, including support for CRO selection, program design, scheduling, study management, and data interpretation.

A toxicologist with over 20 years of experience, Andrew worked in CROs in the United Kingdom and Canada before spending a decade in industry. His efforts there led to the licensing of biodefense products via the Animal Rule compliance program 21 CFR 601.

During his career, Andrew worked with all standard toxicology species (from mice to monkeys) and routes of test agent administration (from oral to intrathecal). In addition to his experience managing nonclinical studies, Andrew has written and reviewed key nonclinical submission documents, including Modules 4, 2.4, and 2.6, and written gap analyses and strategic assessment reports to assist sponsors in lead candidate selection.

Andrew gained his bachelor’s degree in Neuroscience from the University of Sheffield (UK) and a master’s degree in Toxicology from the University of Birmingham (UK). He is a full member of the American College of Toxicology.